Management of dyslipidemia in patients with diabetes

Yu Kataoka, Kiyoko Uno, Stephen J. Nicholls

Research output: Contribution to journalArticle

Abstract

Cardiovascular disease is the leading cause of major morbidity and mortality in patients with type 2 diabetes. The recent focus on the apparent lack of cardiovascular benefit associated with glucose-lowering strategies has overshadowed the importance of targeting dyslipidemia for cardiovascular prevention in patients with diabetes. While lowering low-density lipoprotein (LDL) cholesterol is beneficial, diabetes is also characterized by hypertriglyceridemia, low levels of high-density lipoproteHDL-cholesterol and abundant levels of small, dense LDL particles. Accordingly, these factors represent additional targets for therapeutic modification in order to achieve more effective reductions in cardiovascular risk.

LanguageEnglish
Pages40-45
Number of pages6
JournalUS Endocrinology
Volume7
Issue number1
Publication statusPublished - Aug 2011
Externally publishedYes

Keywords

  • Diabetes mellitus
  • Diabetic dyslipidemia
  • Hypertriglyceridemia
  • Insulin resistance
  • LDL-cholesterol-lowering therapy
  • Low HDL-cholesterol
  • Statin

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism

Cite this

Kataoka, Y., Uno, K., & Nicholls, S. J. (2011). Management of dyslipidemia in patients with diabetes. US Endocrinology, 7(1), 40-45.
Kataoka, Yu ; Uno, Kiyoko ; Nicholls, Stephen J. / Management of dyslipidemia in patients with diabetes. In: US Endocrinology. 2011 ; Vol. 7, No. 1. pp. 40-45.
@article{47c09b642d9e4d58b41b94292cd77943,
title = "Management of dyslipidemia in patients with diabetes",
abstract = "Cardiovascular disease is the leading cause of major morbidity and mortality in patients with type 2 diabetes. The recent focus on the apparent lack of cardiovascular benefit associated with glucose-lowering strategies has overshadowed the importance of targeting dyslipidemia for cardiovascular prevention in patients with diabetes. While lowering low-density lipoprotein (LDL) cholesterol is beneficial, diabetes is also characterized by hypertriglyceridemia, low levels of high-density lipoproteHDL-cholesterol and abundant levels of small, dense LDL particles. Accordingly, these factors represent additional targets for therapeutic modification in order to achieve more effective reductions in cardiovascular risk.",
keywords = "Diabetes mellitus, Diabetic dyslipidemia, Hypertriglyceridemia, Insulin resistance, LDL-cholesterol-lowering therapy, Low HDL-cholesterol, Statin",
author = "Yu Kataoka and Kiyoko Uno and Nicholls, {Stephen J.}",
year = "2011",
month = "8",
language = "English",
volume = "7",
pages = "40--45",
journal = "US Endocrinology",
issn = "1758-3918",
publisher = "Touch Briefings",
number = "1",

}

Kataoka, Y, Uno, K & Nicholls, SJ 2011, 'Management of dyslipidemia in patients with diabetes', US Endocrinology, vol. 7, no. 1, pp. 40-45.

Management of dyslipidemia in patients with diabetes. / Kataoka, Yu; Uno, Kiyoko; Nicholls, Stephen J.

In: US Endocrinology, Vol. 7, No. 1, 08.2011, p. 40-45.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Management of dyslipidemia in patients with diabetes

AU - Kataoka, Yu

AU - Uno, Kiyoko

AU - Nicholls, Stephen J.

PY - 2011/8

Y1 - 2011/8

N2 - Cardiovascular disease is the leading cause of major morbidity and mortality in patients with type 2 diabetes. The recent focus on the apparent lack of cardiovascular benefit associated with glucose-lowering strategies has overshadowed the importance of targeting dyslipidemia for cardiovascular prevention in patients with diabetes. While lowering low-density lipoprotein (LDL) cholesterol is beneficial, diabetes is also characterized by hypertriglyceridemia, low levels of high-density lipoproteHDL-cholesterol and abundant levels of small, dense LDL particles. Accordingly, these factors represent additional targets for therapeutic modification in order to achieve more effective reductions in cardiovascular risk.

AB - Cardiovascular disease is the leading cause of major morbidity and mortality in patients with type 2 diabetes. The recent focus on the apparent lack of cardiovascular benefit associated with glucose-lowering strategies has overshadowed the importance of targeting dyslipidemia for cardiovascular prevention in patients with diabetes. While lowering low-density lipoprotein (LDL) cholesterol is beneficial, diabetes is also characterized by hypertriglyceridemia, low levels of high-density lipoproteHDL-cholesterol and abundant levels of small, dense LDL particles. Accordingly, these factors represent additional targets for therapeutic modification in order to achieve more effective reductions in cardiovascular risk.

KW - Diabetes mellitus

KW - Diabetic dyslipidemia

KW - Hypertriglyceridemia

KW - Insulin resistance

KW - LDL-cholesterol-lowering therapy

KW - Low HDL-cholesterol

KW - Statin

UR - http://www.scopus.com/inward/record.url?scp=84857199118&partnerID=8YFLogxK

M3 - Article

VL - 7

SP - 40

EP - 45

JO - US Endocrinology

T2 - US Endocrinology

JF - US Endocrinology

SN - 1758-3918

IS - 1

ER -

Kataoka Y, Uno K, Nicholls SJ. Management of dyslipidemia in patients with diabetes. US Endocrinology. 2011 Aug;7(1):40-45.